Compare · ORKA vs TKNO
ORKA vs TKNO
Side-by-side comparison of Oruka Therapeutics Inc. (ORKA) and Alpha Teknova Inc. (TKNO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ORKA and TKNO operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- ORKA is the larger of the two at $6.49B, about 13.1x TKNO ($495.7M).
- ORKA has been more active in the news (12 items in the past 4 weeks vs 3 for TKNO).
- ORKA has more recent analyst coverage (11 ratings vs 10 for TKNO).
- Company
- Oruka Therapeutics Inc.
- Alpha Teknova Inc.
- Price
- -
- -
- Market cap
- $6.49B
- $495.7M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- News (4w)
- 12
- 3
- Recent ratings
- 11
- 10
Latest ORKA
- Chief Medical Officer Goncalves Joana exercised 7,000 shares at a strike of $7.32 and sold $706,700 worth of shares (7,000 units at $100.96) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form SCHEDULE 13G filed by Oruka Therapeutics Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Oruka Therapeutics Inc.
- Senior Vice President, Finance Agarwal Arjun exercised 10,000 shares at a strike of $15.69 and sold $1,049,658 worth of shares (10,000 units at $104.97) as part of a pre-agreed trading plan (SEC Form 4)
- Director Ball Kristine M exercised 18,000 shares at a strike of $6.84 and sold $1,888,749 worth of shares (18,000 units at $104.93) as part of a pre-agreed trading plan (SEC Form 4)
- Oruka Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
- SEC Form 10-Q filed by Oruka Therapeutics Inc.
- Oruka Therapeutics to Participate in Multiple Upcoming Conferences
- Chief Executive Officer Klein Lawrence Otto exercised 25,000 shares at a strike of $7.80 and sold $2,390,125 worth of shares (25,000 units at $95.60) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 8-K filed by Oruka Therapeutics Inc.
Latest TKNO
- SEC Form 10-Q filed by Alpha Teknova Inc.
- Alpha Teknova Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Teknova Reports Third Quarter 2026 Financial Results
- Teknova to Report Third Quarter 2026 Financial Results on November 4, 2026
- SEC Form 8-K filed by Alpha Teknova Inc.
- SEC Form 424B5 filed by Alpha Teknova Inc.
- Teknova Announces Pricing of $40 Million Public Offering of Common Stock
- SEC Form 424B5 filed by Alpha Teknova Inc.
- Teknova Announces Proposed Public Offering of Common Stock
- Teknova Announces Preliminary Third Quarter Financial Results